Key result
Targeting NO-cGMP pathways and IL-6 fails to support the systemic inflammation hypothesis in HFpEF.
Why the study?
The comorbidity-driven IL-6-mediated systemic inflammation hypothesis of HFpEF has been extensively evaluated but remains unproven after a decade of randomized controlled trials and mechanistic studies.
A decade of testing, including negative trials of NO-cGMP enhancing drugs and the stopped HERMES trial of ziltivekimab, demonstrates that the IL-6-mediated systemic inflammation hypothesis does not adequately explain the pathophysiology of HFpEF.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The recently announced findings from the HERMES and ATHENA trials with interleukin-6 antagonism with ziltivekimab reinforce the premise that systemic inflammation produced by classical cytokines may not have pathogenic significance in HFpEF.”
Challenges IL-6 inhibition for HFpEF; challenges the comorbidity-driven inflammation paradigm from Paulus-Tschöpe and HERMES.
In 2013, Paulus and Tschöpe proposed that the multitude of comorbidities seen in patients with heart failure with preserved ejection fraction (HFpEF) was causally responsible for triggering an interleukin-6 (IL-6)-mediated systemic inflammatory state that might lead to HFpEF, postulating the intermediary contribution of coronary microvascular disease and deficient nitric oxide/cyclic guanosine monophosphate (NO-cGMP) signaling and cytokine-mediated cardiac hypertrophy and fibrosis. The comorbidity-driven IL-6-systemic inflammation hypothesis has been extensively evaluated in randomized controlled trials. However, in these trials, most comorbidities have not been shown to represent a causal mechanism for systemic inflammation, and the treatment of comorbidities (other than obesity) has not ameliorated HFpEF. Although coronary microvascular dysfunction is common in HFpEF, it is often not endothelium-dependent, and it is not a cause of defective NO-cGMP signaling. Numerous randomized clinical trials with NO-cGMP enhancing drugs (nitrates/nitrites, phosphodiesterase 5 inhibitors and soluble guanylyl cyclase stimulators) have not provided symptomatic or exercise benefits in HFpEF. Mendelian randomization studies link IL-6 to the development of HFpEF; serum levels of IL-6 precede the development and track the severity of HFpEF; and experimental models point to IL-6 as a causal mediator of HFpEF. However, the adipokine hypothesis partitioned IL-6 and other classical cytokines from pathogenic adipokines in identifying molecular mediators of HFpEF, based on the observations that systemic IL-6 does not reliably reflect visceral adipose tissue dysfunction, and it is cosecreted with neutralizing cytokine antagonists. These observations suggested systemic IL-6 represents a distal marker, and not a mediator, of adipose tissue inflammation, and thus, unlikely to play a role in HFpEF. In proteomics analyses, heightened natural endogenous cytokine antagonists are more prominent and consistent features of HFpEF than circulating levels of the cytokines themselves. The HERMES trial tested the efficacy of the IL-6 antibody, ziltivekimab, in patients with HFpEF who were enriched for cytokine-mediated systemic inflammation, but the trial has been stopped for futility. Therefore, as a result of rigorous testing of each of its mechanistic layers, it is now difficult to support the hypothesis that HFpEF is a comorbidity-driven IL-6-mediated systemic inflammatory disorder that acts through or independently of a NO-cGMP deficiency mechanism.
No takes yet. Share an insight, caveat, or question.
Packer et al. (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). IL-6 targeted therapies and NO-cGMP enhancing drugs was evaluated. Clinical trials of NO-cGMP enhancing drugs and the IL-6 antibody ziltivekimab (HERMES trial, stopped for futility) failed to support the IL-6-mediated systemic inflammation hypothesis of HFpEF.
Synapse has enriched 10 related papers. Consider them for comparative context: